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Background: Total cysteine (tCys) in plasma has re-
cently been linked to cardiovascular risk and is also
associated with cardiovascular risk factors, including
body mass index (BMI) and cholesterol. Changes and
predictors of change in tCys concentrations over a mean
follow-up time of 6.0 (5.2–7.2) years were assessed in
this study.
Methods: Baseline data from the Hordaland Homocys-
teine Study recorded in 1992–1993 included tCys, total
homocysteine (tHcy), and various lifestyle and cardio-
vascular risk factors. In 1998–1999, the same measure-
ments were repeated in 3732 individuals born in 1950–
1951 and 3339 individuals born in 1925–1927. Most of the
statistical analyses were done separately in the four age
and sex groups.
Results: The overall mean values of tCys were higher at
follow-up [mean (SD), 296 (41) mol/L] than at baseline
[278 (36.5) mol/L]; P <0.0001. The mean percentage of
increase in tCys in the different age and sex groups
ranged from 4.9% to 8.5%. There was a significant
correlation between the tCys values measured on the
two occasions (Spearman correlation coefficient, 0.55–
0.59 in the different age and sex groups; P <0.0001). The
change in tCys correlated with changes in BMI, choles-
terol, and diastolic blood pressure in the younger age
group, whereas only changes in BMI predicted changes
in tCys in the older age group.
Conclusions: tCys increased in the 6 years between the
two measurements. Factors related to the baseline tCys
values, including BMI and the change in BMI, predicted
the tCys changes over time.
© 2003 American Association for Clinical Chemistry
Increased plasma total homocysteine (tHcy)3 is regarded
as an independent risk factor for occlusive disease in the
coronary, cerebral, and peripheral arteries (1–3).
Homocysteine is produced from the essential amino
acid methionine and is remethylated to methionine. This
reaction is catalyzed by methionine synthase, which re-
quires vitamin B12 as a cofactor and methyltetrahydrofo-
late as a cosubstrate. An alternative route of homocysteine
disposal is degradation to cysteine through the transsul-
furation pathway by two sequential vitamin B6-depen-
dent reactions (4 ).
Cysteine is structurally similar and metabolically
linked to homocysteine. However, the relationship be-
tween plasma total cysteine (tCys) and the risk of cardio-
vascular disease (CVD) has received less attention. Some
studies have shown a relationship between tCys and
vascular occlusive disease (5–9). In these studies, signifi-
cantly higher tCys concentrations were found in vascular
patients than in healthy controls. Data from the European
Concerted Action Project showed a significant U-shaped
relationship between tCys and all cardiovascular disease
categories after adjustment for tHcy, creatinine, and other
cardiovascular disease risk factors (10 ).
We recently investigated the relationship between
plasma tCys and lifestyle and CVD risk factors among
16 176 healthy individuals in the Hordaland Homocys-
teine Study. The strongest determinants of tCys were age,
sex, body mass index (BMI), diastolic blood pressure,
serum total cholesterol, and coffee consumption (11 ).
Plasma tCys and lifestyle and CVD risk factors that
were measured in 1993 in the Hordaland Homocysteine
Study were measured again in 1998 in a subset of 7071
individuals. In the present study, we assessed the stability
of tCys and the determinants of change in plasma tCys
concentrations from 1993 to 1998 in this subset.1 LOCUS for Homocysteine and Related Vitamins and 2 Department of
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Participants and Methods
study population
In 1992–1993, the baseline data for Hordaland Homocys-
teine Study I were collected from three different age
groups: individuals 40–42 years of age (all individuals
living in Hordaland were invited); individuals 43–64
years of age (a 2% random sample of the residents in the
city of Bergen were invited); and individuals 65–67 years
of age (all individuals living in Bergen and three neigh-
boring suburban municipalities were invited). The whole
study population was 18 043 individuals, of whom 96.2%
belonged to the youngest and oldest age groups. Details
on the data collection have been given previously (12 ).
In 1997–1998, 9500 men and women who had partic-
ipated in Hordaland Homocysteine Study I were invited
to a new health screening. They included all living par-
ticipants from the oldest age group (born in 1925–1927)
and the youngest age group (born in 1950–1951) who
were living in Bergen or three neighboring suburban
municipalities. The attendance rate for the whole group
was 74.4%, constituting a total of 7071 participants.
Baseline and follow-up data were collected through
blood tests, questionnaires, and examinations. The ques-
tionnaires provided information about age, lifestyle, and
dietary habits. Coffee consumption was divided into four
groups according to the number of cups consumed per
day: 0, 1–4, 5–8, and9. Smoking was classified into four
categories: never smokers, light smokers (1–9 cigarettes/
day), moderate smokers (10–19 cigarettes/day), and
heavy smokers (20 cigarettes/day).
The examinations included measurements of height,
weight, and blood pressure. For diastolic blood pressure,
three measurements were performed with the Dinamap
845 XT (Criticon). The mean of the second and third
measurements was used in this study. Blood samples
were taken from the participants in the nonfasting state.
Plasma concentrations of tCys and tHcy were determined
by HPLC and fluorescence detection (13, 14). Serum total
cholesterol and triglycerides were measured by enzymatic
methods. In 1998, HDL-cholesterol, serum glucose, creat-
inine, plasma folate, and plasma vitamin B12 were also
measured. The folate and B12 were measured from sam-
ples stored at 20 °C.
The samples were assayed within 2 years of sampling,
and tCys, tHcy (15 ), serum cobalamin (16 ), and blood
lipids were stable under these conditions. Plasma folate
decreased moderately (by30%) during the first year and
remained constant thereafter (16 ).
statistical methods
Differences between values for tCys, BMI, cholesterol,
diastolic blood pressure, and triglycerides measured at
baseline and at follow-up were evaluated statistically by
the paired t-test.
Spearman correlation coefficients were computed be-
tween baseline and follow-up measurements of tCys,
tHcy, cholesterol, diastolic blood pressure, and triglycer-
ides to show the variability in the measurements of these
variables between baseline and follow-up. In addition,
Spearman correlations between CVD risk factors and
plasma tCys measured at follow-up were also computed.
Multiple linear regression models were used to assess
the simultaneous relationships among the various predic-
tors of tCys measured separately at baseline and at
follow-up. Plasma tCys was the response variable,
whereas the predictor variables age, sex, BMI, triglycer-
ides, diastolic blood pressure, total cholesterol, and coffee
consumption were represented in the models as indicator
variables. For each factor, the difference in mean tCys
concentrations between the reference category and the
other categories was estimated by the regression coeffi-
cient. Plasma tCys concentrations across categories of
each risk factor were tested jointly for homogeneity of the
means and for linear trend.
Multiple linear regression was used to assess the
relationship between change in plasma tCys and each of
the predictor variables separately. Changes in tCys be-
tween baseline and follow-up was used as the response
variable, and the baseline risk factor or the change in the
risk factor was used as the predictor variable. The stan-
dardized regression coefficients were the estimates that
would be obtained if all variables in the model were
standardized to zero mean and unit variance before we
performed the regression computations. Each coefficient
indicated the number of SD changes in the dependent
variable associated with a 1 SD change in the independent
variable, holding constant all other variables (17 ). Stan-
dardized coefficients were computed to allow for compar-
ison among the different predictors.
The statistical analyses were performed with SAS sta-
tistical software (release 8.2 for Windows). In addition,
S-PLUS software (Ver. 6.0 for Windows) was used to
construct the graphs for the distribution of absolute
change in tCys between baseline and follow-up.
Results
The overall mean (SD) values of tCys were higher at
follow-up [296.0 (41.0) mol/L] compared with baseline
[278.0 (36.5) mol/L]. The overall mean tCys change was
17.9 (29.7) mol/L, and the mean percentage increase in
tCys in the different age and sex groups was 4.9–8.5%
(Table 1). There was a highly significant correlation be-
tween baseline and follow-up tCys concentrations (Spear-
man correlation coefficient, 0.55–0.59 for the different age
and sex groups; P 0.0001).
The distributions of absolute change in tCys between
baseline and follow-up and the changes in tCys for
baseline values at or below the 10th percentile and at or
above the 90th percentile are shown in Fig. 1. Most of the
participants with low tCys at baseline had an increase in
tCys, whereas those with high tCys at baseline had a
decrease in tCys.
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baseline and follow-up tCys by age and sex
In all age and sex groups, mean tCys concentrations were
higher at follow-up that at baseline (Table 1). In the
younger age group (born in 1950–1951), men had higher
mean tCys than did women at both baseline and follow-
up. In the older age group (born in 1925–1927), there was
no difference between men and women in tCys measured
at baseline. However, follow-up data showed a margin-
ally higher mean tCys in women than in men. The
analyses were repeated separately for participants that
were free from CVD at baseline, and essentially similar
results were obtained (results not shown).
We evaluated the increase in tCys per year in the
cross-sectional data. The increase was evaluated in the
1992–1993 data and the 1998–1999 data separately. In the
1992 data, the increase in tCys per year was 1.1 mol/L in
men and 1.9 mol/L in women. In the 1998 data, the
increase in tCys per year was 1.5 mol/L in men and 2.3
mol/L in women.
The increase in tCys per year was also investigated in
the longitudinal data (from 1992–1993 to 1998–1999). In
the younger men, the increase in tCys was 1.9 mol/L,
and in the younger women, the tCys increase was 2.6
mol/L. For the older age group, the longitudinal in-
crease in tCys was 3.3 mol/L per year in men and 3.9
mol/L per year in women.
baseline and follow-up values for
cardiovascular risk factors by age and sex
The mean values for cholesterol, triglycerides, BMI, and
diastolic blood pressure, measured at baseline and at follow-
up, are presented in Table 2. The results are presented
separately for the younger and older men and women.
In the younger age group, mean values for cholesterol,
triglycerides, and BMI were significantly higher at fol-
low-up than at baseline. Mean diastolic blood pressure
was significantly lower at follow-up compared with base-
line values. The same trends were seen for men and
women. When we compared variables at follow-up and at
baseline, the older age group had lower cholesterol, lower
diastolic blood pressure, and higher BMI at follow-up.
Triglycerides at follow-up were higher in females and
lower in males, but the latter finding was not statistically
significant.
The mean values for creatinine, HDL-cholesterol,
plasma folate, and plasma B12 at follow-up are also
presented in Table 2. In both age groups, women had
higher HDL-cholesterol, plasma folate, and plasma B12
compared with men, whereas men had higher creatinine
than women. Serum creatinine and HDL-cholesterol and
plasma folate and B12 were higher in the older than the
younger age group.
Fig. 1. Distribution of absolute change in plasma tCys between
baseline and follow-up in all participants (top) and in the subgroups
with low (middle) or high tCys (bottom) at baseline.
Low tCys, at or below the 10th percentile at baseline (n  705); High tCys, at or
above the 90th percentile at baseline (n  708). Shaded columns indicate
increases in tCys values; open columns indicate decreases.
Table 1. Mean baseline and follow-up plasma tCys by age and sex.
Age groups Sex n
Mean tCys (95% CI),a mol/L Mean absolute
tCys change
(95% CI), mol/L
Mean % of tCys
changeBaseline Follow-up
All 7071 278.0 (277.2–278.9) 296.0 (295.0–297.0) 17.9 (17.2–18.7) 6.91
Born in 1950–1951 M 1664 270.5 (269.1–271.9) 282.4 (280.9–283.9) 11.8 (10.5–13.2) 4.85
F 2068 250.4 (249.1–251.6) 266.2 (264.9–267.6) 15.9 (14.6–17.1) 6.87
P 0.0001 0.001 0.22
Born in 1925–1927 M 1473 298.1 (296.4–299.8) 318.1 (316.3–320.0) 20.0 (18.4–21.7) 7.24
F 1866 298.0 (296.5–299.6) 321.7 (320.0–323.4) 23.6 (22.2–25.1) 8.45
P 0.94 0.006 0.28
a CI, confidence interval.
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stability over time
The stability of tCys, tHcy, cholesterol, diastolic blood
pressure, and triglyceride measurements over time was
estimated by computing Spearman correlations between
baseline and follow-up measurement for each of these
variables (Table 3). Highly significant correlations were
seen for each of these variables. The correlations were also
calculated in the different age and sex groups separately,
and similar results were obtained. tHcy showed a stron-
ger and more consistent correlation than tCys overall and
in the different age and sex groups (Table 3).
simple correlations between tCys and
cardiovascular risk factors measured at
follow-up
Correlations between CVD risk factors and plasma tCys
measured at follow-up were calculated. Plasma tCys was
strongly correlated with age (r  0.54), BMI (r  0.31),
cholesterol concentration (r  0.25), and creatinine; (r 
0.32). In addition, tCys was weakly associated with tri-
glycerides, diastolic blood pressure, and coffee intake and
negatively associated with HDL-cholesterol. There was no
significant association between tCys and smoking or tCys
and polymorphism in the gene encoding 5,10-methyl-
enetetrahydrofolate reductase (MTHFR 677C3T). Similar
associations were seen for the different age and sex
groups. Nevertheless, coffee intake and cholesterol were
strongly associated with tCys in the younger age group
but not in the older age group.
risk factors measured at baseline and at
follow-up as determinants of tCys at follow-up
Multiple regression analysis was used to identify the
predictors of plasma tCys measured at follow-up (Table
4). For all variables, the difference in mean tCys concen-
Table 2. Mean values and changes for variables at baseline and follow-up by age and sex.
Age groups
Younger Older
Men Women Men Women
n Mean n Mean n Mean n Mean
BMI, kg/m2 1662 2066 1470 1860
Baseline 25.1 23.8 25.7 25.8
Follow-up 26.1 24.9 26.0 26.3
Change 1.0a 1.1a 0.3a 0.4a
Cholesterol, mmol/L 1664 2065 1473 1863
Baseline 5.74 5.39 6.30 7.06
Follow-up 5.84 5.66 5.86 6.59
Change 0.09a 0.27a 0.41a 0.47a
Triglycerides, mg/L 1664 2065 1473 1863
Baseline 1943.5 1193.6 1884.8 1740.6
Follow-up 2069.9 1444.5 1853.2 1800.0
Change 126.4a 250.9a 31.6 59.4b
Diastolic blood pressure, mmHg 1662 2067 1472 1859
Baseline 79.88 75.63 86.08 82.91
Follow-up 78.27 71.84 79.79 75.77
Change 1.61a 3.80a 6.29 7.16a
HDL-cholesterol, mmol/L 1664 2065 1473 1863
Follow-up 1.16 1.45 1.22 1.47
Creatinine, mol/L 1664 2064 1471 1863
Follow-up 95.0 81.6 101.7 86.1
Plasma folate, nmol/L 1656 2055 1458 1853
Follow-up 7.2 8.5 7.5 9.5
Plasma-vitamin B12, pmol/L 1658 2059 1466 1859
Follow-up 370 380 382 405
a,b Paired t-test: a P 0.0001; b P 0.002.
Table 3. Spearman correlations between baseline and
follow-up measurements.a
Age group Sex tCys tHcy Cholesterol
Diastolic
blood
pressure Triglycerides
All 0.72 0.75 0.66 0.61 0.62
Born 1950–
1951
M 0.57 0.71 0.68 0.59 0.56
F 0.55 0.69 0.69 0.66 0.58
Born 1925–
1927
M 0.57 0.71 0.56 0.54 0.57
F 0.59 0.67 0.51 0.56 0.64
a All P 0.0001.
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trations among the categories of each risk factor and the
reference category were estimated. The risk factors as-
sessed at baseline had a significant association with tCys
across different categories of age, sex, BMI, cholesterol,
triglycerides, coffee consumption, and diastolic blood
pressure.
The same analyses were performed with the categories
of the cardiovascular and lifestyle factors measured at
follow-up. Similar results were obtained for most of the
variables (Table 4), but there was no significant associa-
tion between tCys across categories of sex, triglycerides,
and diastolic blood pressure.
changes according to baseline values and
changes in risk factors
The relationship between baseline risk factors and the
change in tCys between baseline and follow-up were
studied by multiple linear regression (Table 5). All anal-
yses were adjusted for sex and age. The standardized
regression coefficients are presented to allow comparison
among the different predictors. The association with
change in tCys was significant with age, BMI, and tri-
glycerides measured at baseline. When the analyses were
performed separately in younger and older men and
women, the significant associations between baseline BMI
and the change in tCys were confined to women. Further-
more, baseline triglycerides had a significant association
with the change in tCys in the younger men and in all
women, but not in the older men.
The relationship between changes in the risk factors
(from baseline to follow-up) and the change in tCys are
also presented in Table 5. Overall, a strong positive
association was seen with change in BMI and total cho-
lesterol. A weaker association was seen with the change in
Table 4. Estimated change in plasma tCys measured at follow-up by risk factors measured at baseline and at follow-up
relative to the reference group in each risk factor.a
Risk factor n At baseline n After 6 yearsb
Age, years
40–42c 3732 3732
65–67 3339 40.36 (38.52–42.21) 3339 41.78 (40.11–43.45)
P-trend 0.0001 0.0001
BMI, kg/m2
20c 318 263
20–24.99 3492 5.12 (1.27–8.96) 2925 5.15 (1.14–9.17)
25–29.99 2658 15.72 (11.73–19.72) 2997 16.03 (11.96–20.11)
30 587 26.47 (21.75–31.18) 873 28.33 (23.81–32.84)
P-trend 0.0001 0.0001
Cholesterol, mmol/L
4.00c 170 128
4.00–5.99 3385 5.34 (0.09–10.59) 3633 6.70 (0.78–12.62)
6.00–7.99 3002 9.86 (4.48–15.23) 3008 12.25 (6.26–18.23)
8.00 508 14.16 (8.06–20.26) 296 16.52 (9.51–23.54)
P-trend 0.0001 0.0001
Triglycerides, mg/L
880c 1403 830
880–1760 3264 2.66 (0.48–4.84) 3548 0.52 (2.00 to 3.05)
1770–2640 1458 4.20 (1.53–6.87) 1664 1.80 (1.09 to 4.69)
2650 940 5.09 (2.01–8.18) 1023 0.82 (2.43 to 4.08)
P-trend 0.0002 0.28
Diastolic blood pressure, mmHg
70c 1142 2118
70–84 3610 1.88 (0.39 to 4.14) 3485 1.31 (0.51 to 3.13)
85–99 1896 2.31 (0.30 to 4.91) 1258 0.79 (1.58 to 3.17)
100 407 6.20 (2.23–10.18) 199 1.09 (3.73 to 5.92)
P-trend 0.0076 0.29
Coffee, cups/day
0c 463 629
1–4 3980 7.61 (5.07–10.16) 4208 7.80 (5.54–10.07)
5–8 1807 10.00 (7.21–12.79) 1572 10.78 (8.16–13.40)
9 228 14.11 (9.10–19.11) 284 9.70 (5.26–14.14)
P-trend 0.0001 0.0001
a 95% confidence intervals in parentheses.
b Adjusted for all risk factors in this table and for sex and creatinine.
c Reference group.
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diastolic blood pressure, and a weak negative association
was seen with the change in triglycerides. The analyses
were adjusted for sex, age, and creatinine measured at
follow-up. The addition of creatinine to the model only
slightly weakened the results. Analysis of subgroups
demonstrated that in the older age group, only the
association with BMI was significant, whereas the other
variables, including change in cholesterol, were not asso-
ciated with tCys changes.
The change in tCys was evaluated in different catego-
ries of change in BMI from baseline to follow-up (Table 6).
The results showed that, on average, tCys decreased in
individuals whose BMI decreased from baseline to follow-
up, whereas tCys increased in individuals who had an
increase in BMI higher than one unit at follow-up com-
pared with baseline. There was no significant change in
tCys when BMI was not changed or was slightly increased
(less than one unit of change).
Discussion
Using data on 7071 participants from the Hordaland
Homocysteine Study, we assessed the changes in plasma
tCys and the corresponding changes in the determinants
of tCys from 1992–1993 to 1998. The results show that
tCys was significantly higher at follow-up compared with
baseline in both the younger and older age groups. The
determinants of change were different for the older and
younger groups. In the younger group, changes in BMI,
cholesterol, and diastolic blood pressure were the stron-
gest predictors of change in tCys, whereas only a change
in BMI determined the change in tCys in the older age
group (Table 5).
The major strength of our study is the large number of
participants, which allowed us to assess the changes in
several lifestyle and CVD risk factors and the changes in
tCys over a period of 6 years. The lack of measurements of
creatinine, folate, and vitamin B12 at baseline is a weak-
ness in this study because the changes in these factors
could not be evaluated. Participants with low tCys at
baseline had an increase in plasma tCys, whereas those
with high tCys at baseline had a decrease in tCys (Fig. 1).
This might be attributable to changes in tCys determi-
nants within these individuals, but this observation prob-
ably reflects the phenomenon of regression toward the
mean (18 ).
We evaluated the increase in tCys on a per year of age
Table 5. Standardized linear regression coefficients for tCys change per SD of the predictor variable.a
Regression coefficients
All
Younger Older
Men Women Men Women
Baseline risk factorb
Age 0.14c
BMI, kg/m2 0.04c 0.03 0.07c 0.003 0.06c
Weight, kg 0.05c 0.05 0.06c 0.007 0.07c
Total cholesterol, mmol/L 0.01 0.01 0.02 0.03 0.03
Diastolic blood pressure, mmHg 0.01 0.02 0.01 0.02 0.03
Triglycerides, mg/L 0.08c 0.11c 0.12c 0.05 0.05c
Coffee, cups/day 0.0002 0.003 0.03 0.04 0.004
Change in risk factord
BMI, kg/m2 0.09c 0.13c 0.09c 0.09c 0.07c
Weight, kg 0.07 0.09c 0.08c 0.01 0.07c
Total cholesterol, mmol/L 0.07c 0.11c 0.14c 0.03 0.02
Diastolic blood pressure, mmHg 0.03c 0.07c 0.09c 0.02 0.04
Triglycerides, mg/L 0.04c 0.08c 0.03 0.04 0.03
Coffee, cups/day 0.02 0.04 0.004 0.06c 0.01
a Change in tCys (in SD units) per 1 SD change in the predictor variable.
b Adjusted for age and sex.
c P 0.05.
d Adjusted for age, sex, and creatinine.
Table 6. Change in tCys (mol/L) with change in BMI.
BMI change, kg/m2 n All
Younger Older
n Men n Women n Men n Women
0 2132 3.69a 345 4.30a 479 3.99a 600 3.47a 708 3.33a
0–1 2106 0.33 538 2.43 587 1.49 479 2.07 502 1.00
1 2817 3.60a 778 5.10a 999 4.09a 391 1.99 649 2.63a
a P 0.05.
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basis. For the younger age group, there was general
agreement between the cross-sectional and longitudinal
findings, with an increase of 1.1–2.6 mol/L per year in
men and women. In the older age group, however, there
was an increase in tCys in the longitudinal data beyond
that expected from the cross-sectional data. We speculate
that the increase in tCys in the older age group may be
attributable to a decline in renal function, a condition that
is associated with an increase in tCys and is common in
the elderly. In both the younger and older age groups,
however, a slight calendar time effect toward increasing
tCys in the population cannot be ruled out.
Correlations between baseline and follow-up (self-
correlations) were calculated to assess the stability of tCys
and other metabolites between baseline and follow-up.
tCys showed more stability and stronger correlations than
did cholesterol, diastolic blood pressure, and triglycerides
(Table 3). Both tCys and tHcy were stable over the 6-year
follow-up time, as demonstrated by the strong self-
correlations of each of these amino thiols. However, tCys
showed a slightly weaker self-correlation than did tHcy,
particularly when the correlations were assessed for the
different age and sex groups separately. There are no
studies on the stability of tCys over time. However, a few
studies have evaluated the short- and long-term variabil-
ity of tHcy. Clarke et al. (19 ) showed that an individual’s
plasma tHcy is relatively constant over a 1-year period,
with little seasonal variation. Garg et al. (20 ) found that an
individual’s plasma tHcy is relatively constant over at
least 1 month but that the variability increases over 30
months, a result confirmed by Clarke et al. (21 ), who
found that the variability in tHcy increases with longer
intervals between measurements.
The determinants of tCys were previously studied in
this population, using the baseline data (11 ). In the
present study, the determinants of tCys were evaluated
again, using the follow-up data. The determinants of tCys
were mainly the same for follow-up as for baseline values.
Age, sex, BMI, cholesterol, and coffee consumption were
among the strongest predictors of tCys at follow-up.
Diastolic blood pressure, which was a strong determinant
of tCys at baseline, had no relationship with tCys at
follow-up. The decrease in diastolic blood pressure from
baseline to follow-up, however, may indicate effects from
medication and/or changes in lifestyle, which in turn may
explain this lack of association between tCys and diastolic
blood pressure at follow-up.
Creatinine, which was measured at follow-up but not
at baseline, was a strong determinant of tCys. Likewise,
Brattstro¨m et al. (22 ) found that creatinine was a strong
determinant of tCys. Plasma folate and B12 were also
measured in the present study, and the results showed
weak associations between tCys and both folate and B12.
We have previously found associations between tCys and
creatinine and tCys and folate but not B12 in the European
Concerted Action Project (10 ).
BMI and cholesterol are strong predictors of tCys at
baseline (11 ) and at follow-up (Table 3). In the present
study, the change in each of these risk factors was a strong
predictor of change in plasma tCys in the younger age
group. In the older age group, however, mean cholesterol
concentrations were lower at follow-up compared with
baseline values, possibly because of changes in lifestyle or
the use of cholesterol-lowering medications. The differ-
ence in patterns observed between the older and the
younger groups was not attributable to the higher mor-
tality in participants with high cholesterol at baseline
(data not shown). Other factors, e.g., a decline in renal
function, could be responsible for the increase in tCys in
this older age group (23 ). This is reflected in the strong
association between tCys and creatinine (Table 4) and in
the high creatinine values in the older age groups com-
pared with the younger groups (Table 2). Creatinine was
measured only in the follow-up data; therefore, changes
in plasma creatinine between baseline and follow-up
could not be determined.
BMI was the strongest determinant of tCys in both men
and women and in both age groups. The increase in tCys
was confined to those with a greater than one unit
increase in BMI between baseline and follow-up (Table 6).
The mechanism(s) behind the association of plasma tCys
with serum cholesterol and BMI is unknown. The possi-
bility that tCys concentrations are related to body cell
mass (24 ) is unlikely because the increase in BMI in our
study participants probably reflects an increase in body
fat rather than muscle.
In conclusion, this is the first study on changes in tCys
and its determinants with time. The results demonstrated
an increase in tCys during a 6-year period with a strong
correlation between the two measurements. The changes
in cholesterol and diastolic blood pressure, which were
determinants of baseline tCys values, were also predictors
of the change in tCys with time. The change in BMI,
however, emerged as the strongest determinant of change
in tCys in all age and sex groups.
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